CTOs on the Move

BioSig Technologies

www.biosigtech.com

 
BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.biosigtech.com
  • 8441 Wayzata Blvd Ste 240
    Minneapolis, MN USA 55426
  • Phone: 763.999.7330

Executives

Name Title Contact Details

Similar Companies

Orgain

Orgain, Inc. was founded by Andrew Abraham M.D. in 2008 . Orgain is the world's first organic drinkable meal on-the-go and is used by physicians, top nutritionists, professional athletes, and health conscious consumers across the nation. Orgain is nationally distributed at Whole Foods, Wegman's, Walgreens, CVS, Rite-Aid, Sprouts, Vitamin Shoppe, Mother's Market, Fairway Markets and many more -- over 15,000 retailers!

MassPRO

MassPRO is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Champion Nutrition Inc

Champion Nutrition Inc is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Physician Billing Service Bureau

Physician Billing Service Bureau is a Dearborn Heights, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Assembly Biosciences

Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly`s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. We pride ourselves on creating a culture and work environment that is scientifically driven, ambitious, and collaborative. We encourage diversity of thought that leads to great innovation and are looking to add to our dynamic team great people who are driven to transform the lives of patients. We believe our Microbiome platform represents a best in class approach to developing biopharmaceutical agents from live biotherapeutic products. ABI-M201, our lead program in mildly to moderately active ulcerative colitis (UC), is currently in a phase 1b clinical trial. This program is part of a broader collaboration we established with Allergan in 2017 for gastrointestinal programs such as UC, Crohn`s disease and Irritable Bowel Syndromes with potential total development and commercial milestones of up to $2.8 billion. Our internal pipeline comprises first in class or best in class live microbial biotherapeutic approaches in areas such as oncology, immune mediated and metabolic disorders, and other areas of high medical need. Assembly is headquartered in Carmel, Indiana, while the R&D headquarters is in South San Francisco. The Company also has a microbiome manufacturing facility in Groton, CT, and offices in China.